Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC

Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC

Background: Limited data are available on late immune-related adverse events (IRAEs) in patients with metastatic NSCLC receiving immunotherapy (ICI) beyond 2 years. Methods: A single-institution retrospective analysis including patients who received longer than 2 years of ICI therapy for metastatic...

Full description

Saved in:
Bibliographic Details
Main Authors: Omar Elghawy, MD, Adam Barsouk, MD, Jonathan H. Sussman, BS, Benjamin A. Bleiberg, MD, Lauren Reed-Guy, MD, Christopher D’Avella, MD, Aditi Singh, MD, Christine Ciunci, MD, MSCE, Kyle Robinson, MD, John Kosteva, MD, Corey Langer, MD, Roger B. Cohen, MD, Charu Aggarwal, MD, MPH, Melina Marmarelis, MD, MSCE, Lova Sun, MD, MSCE
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:JTO Clinical and Research Reports
Subjects:
Immunotherapy
Non–small cell lung cancer
Immune-related adverse events
Drug toxicity
Overall survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000682
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666364325000682

Similar Items